Moderate to Severe Atopic Dermatitis Clinical Trial
Official title:
A Prospective, Observational Study of Canadian Patients Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD (msAD) according to the Canadian-specific prescribing information (in accordance with the Canadian Dupixent Product Monograph). The study will be conducted in approximately 30 centers in Canada to assess participants of all ethnicities and races. At each participating site, all AD participants who receive an initial prescription for Dupixent will be invited to participate in this study, until the Canadian enrollment goal is achieved.
The duration of the study for each participant will be of 18 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06012812 -
A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT05549947 -
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
|
Phase 2 | |
| Recruiting |
NCT06136741 -
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT03568162 -
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT00148746 -
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
|
N/A | |
| Recruiting |
NCT05702268 -
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Not yet recruiting |
NCT06468956 -
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT05997927 -
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Not yet recruiting |
NCT05197023 -
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
|
Phase 1 | |
| Recruiting |
NCT06239311 -
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
|
Phase 3 | |
| Terminated |
NCT01286220 -
Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis
|
N/A | |
| Completed |
NCT02426359 -
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
|
Phase 2 |